HomeCompareTAIPY vs ADC

TAIPY vs ADC: Dividend Comparison 2026

TAIPY yields 14.29% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $139.9K in total portfolio value· pulled ahead in Year 6
10 years
TAIPY
TAIPY
● Live price
14.29%
Share price
$14.00
Annual div
$2.00
5Y div CAGR
-8.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.1K
Annual income
$1,041.05
Full TAIPY calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — TAIPY vs ADC

📍 ADC pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTAIPYADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TAIPY + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TAIPY pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TAIPY
Annual income on $10K today (after 15% tax)
$1,214.29/yr
After 10yr DRIP, annual income (after tax)
$884.89/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $66,815.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TAIPY + ADC for your $10,000?

TAIPY: 50%ADC: 50%
100% ADC50/50100% TAIPY
Portfolio after 10yr
$107.0K
Annual income
$40,344.14/yr
Blended yield
37.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

TAIPY
No analyst data
Altman Z
13.5
Piotroski
6/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TAIPY buys
0
ADC buys
7
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$ADC▼ Sell$15,001 - $50,0002026-01-15
Lisa McClain🏢 House$ADC▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$ADC▲ Buy$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$ADC▼ Sell$1,001 - $15,0002025-06-17
Lisa McClain🏢 House$ADC▼ Sell$1,001 - $15,0002025-06-17
Lisa McClain🏢 House$ADC▲ Buy$1,001 - $15,0002025-06-11
Lisa McClain🏢 House$ADC▲ Buy$1,001 - $15,0002025-06-11
Josh Gottheimer🏢 House$ADC▼ Sell$1,001 - $15,0002025-04-09
Josh Gottheimer🏢 House$ADC▲ Buy$1,001 - $15,0002024-04-15
Josh Gottheimer🏢 House$ADC▼ Sell$1,001 - $15,0002024-03-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTAIPYADC
Forward yield14.29%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.8%40.4%
Portfolio after 10y$37.1K$176.9K
Annual income after 10y$1,041.05$79,647.25
Total dividends collected$12.4K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: TAIPY vs ADC ($10,000, DRIP)

YearTAIPY PortfolioTAIPY Income/yrADC PortfolioADC Income/yrGap
1$12,003$1,302.86$10,987$577.21+$1.0KTAIPY
2$14,176$1,332.88$12,293$855.34+$1.9KTAIPY
3$16,510$1,341.75$14,088$1,290.70+$2.4KTAIPY
4$18,998$1,331.92$16,660$1,994.91+$2.3KTAIPY
5$21,634$1,306.29$20,525$3,181.85+$1.1KTAIPY
6← crossover$24,416$1,267.90$26,654$5,286.90$2.2KADC
7$27,345$1,219.66$37,006$9,259.47$9.7KADC
8$30,423$1,164.26$55,862$17,338.74$25.4KADC
9$33,657$1,104.05$93,452$35,300.32$59.8KADC
10$37,054$1,041.05$176,931$79,647.25$139.9KADC

TAIPY vs ADC: Complete Analysis 2026

TAIPYStock

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Full TAIPY Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this TAIPY vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TAIPY vs SCHDTAIPY vs JEPITAIPY vs OTAIPY vs KOTAIPY vs MAINTAIPY vs NNNTAIPY vs EPRTTAIPY vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.